Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1”

2,787 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,787 results

Not applicableStudy completedNCT06607809
What this trial is testing

Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC

Who this might be right for
Metastatic Renal Cell Carcinoma
Dr. Lutfi Kirdar Kartal Training and Research Hospital 99
Large-scale testing (Phase 3)Ended earlyNCT04335006
What this trial is testing

Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 80
Testing effectiveness (Phase 2)Study completedNCT05509699
What this trial is testing

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Extensive-Stage Small Cell Lung Cancer
Hutchison Medipharma Limited 21
Large-scale testing (Phase 3)Active Not RecruitingNCT04380636
What this trial is testing

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 870
Testing effectiveness (Phase 2)Looking for participantsNCT07332247
What this trial is testing

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC

Who this might be right for
Nasopharangeal CancerRecurrent Nasopharynx Carcinoma
Sun Yat-sen University 94
Testing effectiveness (Phase 2)Active Not RecruitingNCT06056804
What this trial is testing

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Beijing Friendship Hospital 20
Testing effectiveness (Phase 2)WithdrawnNCT04149275
What this trial is testing

Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Who this might be right for
Carcinosarcoma of OvaryCarcinosarcoma of UterusCarcinosarcoma of Vagina
University of Alabama at Birmingham
Testing effectiveness (Phase 2)UnknownNCT05193214
What this trial is testing

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Who this might be right for
Sarcoma, Soft Tissue
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07157306
What this trial is testing

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 35
Large-scale testing (Phase 3)Looking for participantsNCT05862064
What this trial is testing

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Fudan University 606
Testing effectiveness (Phase 2)Active Not RecruitingNCT05012371
What this trial is testing

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Who this might be right for
Advanced Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8+1 more
M.D. Anderson Cancer Center 90
Very early researchNot Yet RecruitingNCT07389187
What this trial is testing

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
mCRPC
Shanghai Changzheng Hospital 10
Not applicableActive Not RecruitingNCT05757206
What this trial is testing

The Syn-Sleep Study

Who this might be right for
REM Sleep Behavior Disorder (iRBD)
CND Life Sciences 80
Early research (Phase 1)UnknownNCT05019534
What this trial is testing

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E-mutated /MSS Metastatic Colorectal CancerVemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
West China Hospital 12
Not applicableStudy completedNCT05142709
What this trial is testing

Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

Who this might be right for
Metastatic Esophageal Squamous Cell Carcinoma
Fudan University 1,197
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT02971748
What this trial is testing

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Who this might be right for
Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Breast Inflammatory Carcinoma+2 more
M.D. Anderson Cancer Center 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05640726
What this trial is testing

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Who this might be right for
Rectal Cancer
Fujian Cancer Hospital 30
Not applicableLooking for participantsNCT06327178
What this trial is testing

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Who this might be right for
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Nanfang Hospital, Southern Medical University 20
Load More Results